2023 World Conference on Lung Cancer (Posters)-P2.10. Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors

P2.10. Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors - PDF(Slides)

Back to course

Pdf Summary

A retrospective study of 150 Swedish patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) was conducted to evaluate the effectiveness of tyrosine kinase inhibitors (TKIs) and resistance mechanisms. The study included patients treated with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib between January 2009 and December 2021. The median progression-free survival (PFS) and overall survival (OS) for patients treated with crizotinib were 8 months and 35 months, respectively. The median PFS for second-generation ALK TKIs was 52 months, with an overall response rate of 91.4%. Patients with secondary ALK mutations had a significantly worse median PFS during the next treatment line of ALK inhibitors compared to those without resistance mutations. There were no significant differences in PFS or OS between different EML4-ALK variants. These findings suggest that second-generation ALK TKIs may provide better outcomes compared to crizotinib. However, resistance to ALK TKIs is still a challenge and secondary mutations can impact treatment effectiveness. Further research is needed to better understand the mechanisms of resistance and to develop strategies to overcome it.

Asset Subtitle

Per Hydbring

Meta Tag

Speaker Per Hydbring

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

retrospective study

Swedish patients

ALK-positive NSCLC

tyrosine kinase inhibitors

crizotinib

second-generation ALK TKIs

resistance mechanisms

PFS

ALK mutations